RÉSUMÉ
BACKGROUND: Congenital toxoplasmosis is associated with severe complications. German state health insurance covers rubella, but not toxoplasmosis, immunity screening. We analysed the effect of socioeconomic factors on the efficiency of private toxoplasmosis screening during pregnancy. METHODS: Toxoplasmosis and rubella screening data (n = 5402 mothers) were collected within the population-based Survey of Neonates in Pomerania (SNiP). RESULTS: At the first-trimester screening, 34.4 % (88.1 %) of expecting mothers were immune to toxoplasmosis (rubella). Susceptibility for toxoplasmosis (rubella) was observed in 39.6 % (8.9 %) and 25.8 % (2.95 %) were not tested. Data on a 2(nd) screening were available in a subgroup of women with negative immunity showing less than 45 % participation rate. Active toxoplasmosis (no rubella) infection was observed in 0.3 % (n = 17) of pregnant women. A multiple logistic regression model (AIC = 719.67; AUC = 0.725) revealed that the likelihood of participating in a second toxoplasmosis screening increased among women with a good level of education and a steady partnership and decreased with paternal unemployment and the absence of breastfeeding. The highest probability of non-participation in toxoplasmosis screening was found among women with temporal burden and family responsibilities. A cost-benefit analysis showed that covering general screening for toxoplasmosis with health insurance saved costs. CONCLUSION: Toxoplasmosis carried a substantial risk of infection during pregnancy. Although increased socioeconomic status was positively associated with the participation in toxoplasmosis screening, this was not the case when pregnant women had strong temporal burden and family responsibilities. This data supports the need for toxoplasmosis screening among pregnant women as a general healthcare benefit covered by insurance.
Sujet(s)
Dépistage de masse/économie , Acceptation des soins par les patients/statistiques et données numériques , Complications parasitaires de la grossesse/diagnostic , Diagnostic prénatal/économie , Facteurs socioéconomiques , Toxoplasmose/diagnostic , Adulte , Femelle , Allemagne , Humains , Couverture d'assurance/économie , Dépistage de masse/méthodes , Dépistage de masse/psychologie , Acceptation des soins par les patients/psychologie , Grossesse , Complications parasitaires de la grossesse/économie , Complications parasitaires de la grossesse/psychologie , Diagnostic prénatal/méthodes , Diagnostic prénatal/psychologie , Toxoplasma , Toxoplasmose/économie , Toxoplasmose/psychologie , Jeune adulteRÉSUMÉ
We present the youngest pediatric patient so far with febrile ulcerative Mucha-Haberman disease (FUMHD) after an admitting clinical picture of hemorrhagic varicella infection. With a time to diagnosis of 25 days, the 20-month-old boy responded to low dose cyclosporine and prednisolone given for 3 months and is free of disease after 4 years of follow up. We describe a polyclonal CD8+ T cell response with elevated pro-inflammatory cytokines and a fivefold upregulation of the high-affinity Fc receptor type I (CD64) on granulocytes. Early consideration of FUMHD in the differential diagnosis of a systemic inflammatory disease combined with a generalized necrotizing rash is important for early and adequate management of children with this rare and challenging disease.
Sujet(s)
Varicelle/complications , Herpès/diagnostic , Herpès/anatomopathologie , Pityriasis lichénoïde/diagnostic , Pityriasis lichénoïde/anatomopathologie , Antibactériens/administration et posologie , Anti-inflammatoires/administration et posologie , Lymphocytes T CD8+/immunologie , Ciclosporine/administration et posologie , Granulocytes/composition chimique , Granulocytes/immunologie , Herpès/traitement médicamenteux , Humains , Nourrisson , Mâle , Pityriasis lichénoïde/traitement médicamenteux , Prednisolone/administration et posologie , Récepteurs du fragment Fc des IgG/analyse , Résultat thérapeutiqueRÉSUMÉ
INTRODUCTION AND OBJECTIVES: Determination of the efficacy of an early ultrasound examination followed by immediate treatment of hip joint dysplasia as well as measuring the therapeutic success in a population-based cohort study of neonates. MATERIAL AND METHODS: The Survey of Neonates in Pomerania (SNiP) study included 4,093 neonates which represents 95.1 % of the total neonatal population. Of these children 2,534 (61.9 %) underwent ultrasound examination of the hip joint during the U2 stage (3-10 days after birth). The mean gestational age was 38.9 weeks. The sonographic classification was performed according to Graf. RESULTS: Initially (U2 stage) 42 (1.66 %) children were reported to be in need of therapy (stage IIc or higher according to Graf). The analysis showed a significantly higher incidence in girls (32 girls vs. 10 boys, p < 0.023, χ(2) test) and in children who had a breech birth (116, 4.6 %). A genetic predisposition was ascertained in 180 (7.1 %) children. The children could be subdivided into two groups: 1) children who underwent hip joint ultrasound during both U2 and U3 and 2) children who were first screened at the U3 stage. Of the 49 out of 54 neonates where the ultrasound findings were positive at the U2 examination the hip joint was matured in 32 children at U3 (4-8 weeks), 11 children had to be treated for 8-12 weeks 5 children were treated for over 3 months and1 child needed surgical correction. CONCLUSION: The early diagnosis of hip maturation disorders and joint dysplasia facilitates early implementation of effective treatment. At our clinic over 60 % of the infants underwent the U2 check up and, given a pathological finding, could undergo early treatment. It was possible to successfully treat 78 % of these children with a Tübingen hip flexion splint in just 4-8 weeks. In contrast, infants who were first examined at the U3 stage needed treatment for 4-12 months. In our opinion, early diagnosis at the age of 3-10 days should be carried out for all newborns.
Sujet(s)
Luxation de la hanche/imagerie diagnostique , Luxation de la hanche/thérapie , Attelles/statistiques et données numériques , Échographie/statistiques et données numériques , Femelle , Allemagne/épidémiologie , Luxation de la hanche/épidémiologie , Humains , Incidence , Nouveau-né , Mâle , Facteurs de risque , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: A catheter lock solution containing 1.35% taurolidine and 4% citrate could potentially disrupt bacterial surface adherence and consecutive biofilm production due to the anti-adherence properties of taurolidine and the anticlotting and chelator activities of both compounds. AIM: To compare the impact on microbial catheter colonization and infectious complications of heparin and taurolidine citrate as central venous catheter (CVC) lock solutions in paediatric patients with haematological malignancies. METHODS: Seventy-one patients aged 1.4-18 years were randomized to two treatment groups using either heparin (N = 36) or taurolidine citrate (N = 35). Infectious complications and clinical side-effects were prospectively monitored and microbial colonization of catheters was assessed at the time of removal. FINDINGS: There were two bloodstream infections in the taurolidine citrate group versus nine in the heparin group (0.3 vs 1.3 infections per 1000 catheter-days; P = 0.03). Fever of unknown origin and catheter occlusions were observed with a similar frequency in both groups. Microbial colonization was found in 25.4% catheters. The time of no-lock use, but not the type of lock solution or time of observation, was a significant predictor of catheter colonization (P = 0.004). Colonization was not observed in CVCs used immediately with taurolidine citrate lock. Seven patients in the taurolidine citrate group (20%) experienced side-effects (nausea, vomiting, abnormal taste sensations). CONCLUSION: The use of taurolidine citrate lock solution was associated with a significant reduction in bloodstream infection in immunocompromised paediatric patients. Taurolidine citrate may prevent colonization of CVCs if used from the time of insertion, but not after a period of no-lock catheter use.
Sujet(s)
Anti-infectieux locaux/pharmacologie , Anticoagulants/pharmacologie , Cathéters à demeure/microbiologie , Héparine/pharmacologie , Taurine/analogues et dérivés , Thiadiazines/pharmacologie , Adolescent , Bactéries/isolement et purification , Infections sur cathéters/épidémiologie , Infections sur cathéters/prévention et contrôle , Cathétérisme/méthodes , Enfant , Enfant d'âge préscolaire , Femelle , Fièvre d'origine inconnue/épidémiologie , Fièvre d'origine inconnue/prévention et contrôle , Tumeurs hématologiques/thérapie , Humains , Incidence , Nourrisson , Mâle , Analyse de survie , Taurine/pharmacologieRÉSUMÉ
OBJECTIVES: Aqueous Viscum album L. extracts are widely used for anti-cancer therapies. Due to their low solubility, triterpenes (which are known to act on cancers), do not occur in aqueous extracts in significant amounts. Using cyclodextrins, we have found it possible to solubilize mistletoe triterpene acids and to determine their effects on acute lymphoblastic leukaemia (ALL) in vitro and in vivo. MATERIALS AND METHODS: A C.B-17/SCID model of pre-B ALL (NALM-6) was used to test efficacy and mechanisms of treatment with lectin- and triterpene acid containing preparations in vivo. Cytotoxicity of increasing concentrations of V. album L. preparations was assessed in vitro. Apoptosis was determined using mitochondrial membrane potential measurements, annexin V/PI, western blot analyses and caspase inhibitor assays. RESULTS: Solubilized triterpene acid- or lectin-containing V. album L. extracts inhibited cell proliferation and demonstrated cytotoxic properties in vitro. Annexin V/PI and mitochondrial membrane potential assays indicated that dose-dependent induction of apoptosis was the main mechanism. Combination (viscumTT) of lectin- (viscum) and triterpene-containing (TT) extracts resulted in greatest induction of apoptosis. Furthermore, caspase activity demonstrated that these extracts were able to induce apoptosis through both caspase-8 and -9 dependent pathways. In vivo experimentation showed that treatment of mice with viscumTT combination prolonged mean survival to 50.5 days compared to 39.3 days in the phosphate-buffered saline group. CONCLUSION: Here for the first time, we have demonstrated that either solubilized triterpene acids or lectins and combinations thereof, induce dose-dependent apoptosis in the ALL cell line NALM-6 via caspase-8 and -9 dependent pathways.
Sujet(s)
Antinéoplasiques d'origine végétale/administration et posologie , Phytothérapie , Leucémie-lymphome lymphoblastique à précurseurs B et T/traitement médicamenteux , Triterpènes/administration et posologie , Viscum album/composition chimique , Animaux , Antinéoplasiques d'origine végétale/isolement et purification , Apoptose/effets des médicaments et des substances chimiques , Caspase-3/métabolisme , Caspase 8/métabolisme , Caspase-9/métabolisme , Lignée cellulaire tumorale , Prolifération cellulaire/effets des médicaments et des substances chimiques , Cytochromes c/métabolisme , Synergie des médicaments , Femelle , Humains , Potentiel de membrane mitochondriale/effets des médicaments et des substances chimiques , Souris , Souris SCID , Acide oléanolique/administration et posologie , Extraits de plantes/administration et posologie , Extraits de plantes/isolement et purification , Lectines végétales/administration et posologie , Lectines végétales/isolement et purification , Leucémie-lymphome lymphoblastique à précurseurs B et T/métabolisme , Leucémie-lymphome lymphoblastique à précurseurs B et T/anatomopathologie , Solubilité , Triterpènes/isolement et purification , Tests d'activité antitumorale sur modèle de xénogreffeRÉSUMÉ
OBJECTIVE: Acupuncture is successfully used to alleviate vomiting in children after general anesthesia. However there is no data on treatment of vomiting in children with gastroenteritis (GE) and pneumonia (PM). METHODS: Descriptive analysis of 18 cases, where acupuncture was used as an individual therapy attempt to treat vomiting in children with GE or PM before starting the conventional antiemetic therapy. Feasibility and acceptance by patients and parents as well as the incidence of vomiting and use of antiemetic drugs after acupuncture were recorded. RESULTS: Acupuncture was feasible in all children and application of the indwelling needles was tolerated without fear. Side effects were not observed. 13 patients stopped vomiting immediately after the insertion of acupuncture needles, none of the patients required conventional antiemetic medication. CONCLUSION: Acupuncture for the treatment of vomiting is feasible and acceptable. Suggested antiemetic effect should be examined in a randomized multicenter controlled trial.
Sujet(s)
Acupuncture auriculaire/instrumentation , Gastroentérite/thérapie , Pneumopathie infectieuse/thérapie , Vomissement/thérapie , Points d'acupuncture , Maladie aigüe , Enfant , Enfant d'âge préscolaire , Études de faisabilité , Femelle , Humains , Nourrisson , Durée du séjour , Mâle , Aiguilles , Acceptation des soins par les patients , Satisfaction des patients , Études rétrospectivesRÉSUMÉ
The induction of T-cell mediated immunity against neuroblastoma is a challenge due to poor immunogenicity of this malignancy. Here, we demonstrate the induction of protective immunity in a syngeneic murine neuroblastoma model following vaccination with minigenes comprising of three novel natural MHC class I ligands. First, after immunoprecipitation of MHC class I from NXS2 cells, peptides were eluted and examined in tandem-MS analysis which lead to the identification of three novel natural MHC class I peptide ligands, TEALPVKLI from ribonucleotide reductase M2, NEYIMSLI from Ser/Thr protein phosphatase 2A and FEMVSTLI with unknown origin. Second, we constructed two different minigenes, one encoding for the three novel epitopes and the second for three known mTH derived epitopes with high predicted binding affinity to MHC class I by cloning them into the mammalian expression vector pCMV-3FUB. This lead to constructs with an ubiquitin-tag upstream the inserted epitopes in order to facilitate proteasomal degradation. Furthermore the epitopes were separated by a spacer peptide (AAY), which proved to be a preferential proteasome cleavage site. Third, we demonstrate the induction of protective immunity against neuroblastoma using an attenuated strain of Salmonella typhimurium as a carrier harboring pCMV 3FUb vectors encoding for the two minigenes. These findings establish proof of concept that disruption of self tolerance against neuroblastoma associated epitopes may be an effective adjuvant therapeutic strategy.
Sujet(s)
Autoantigènes/génétique , Tumeurs du foie/prévention et contrôle , Neuroblastome/prévention et contrôle , Vaccination , Vaccins à ADN , Animaux , Sites de fixation , Lymphocytes T CD8+/immunologie , Épitopes/immunologie , Épitopes/métabolisme , Femelle , Immunité cellulaire , Ligands , Tumeurs du foie/immunologie , Tumeurs du foie/secondaire , Souris , Neuroblastome/immunologie , Neuroblastome/secondaire , Fragments peptidiques/métabolisme , Phosphoprotein Phosphatases/composition chimique , Plasmides , Protein Phosphatase 2 , Ribonucleoside diphosphate reductase/composition chimique , Salmonella typhimurium/génétiqueRÉSUMÉ
Tumor directed cytotoxic therapy is one of the major challenges for the success of chemotherapy. In order to accomplish this goal in neuroblastoma, we rationally designed a prodrug of etoposide as substrate for tyrosine hydroxylase, a well established neuroblastoma associated enzyme. Here, we report synthesis and characterization of a 3,4 dihydroxy-phenyl carbamate derivative of etoposide. In order to demonstrate activation by tyrosine hydroxylase, the coding sequence of murine tyrosine hydroxylase was generated by reverse transcriptase-polymerase chain reaction from NXS2 neuroblastoma cells and cloned into the pRSET-A bacterial expression vector. The enzyme was expressed in Escherichia coli, characterized by Western blot and enzymatic activity was demonstrated by conversion of tyrosine into DOPA in the presence of cofactors using reversed phase high-performance liquid chromatography. Under these enzymatic conditions, we demonstrate conversion of 3,4 dihydroxy-phenyl carbamate prodrug into free etoposide. This effect was clearly mediated by the enzyme since bacteria transformed with the empty vector were ineffective of prodrug activation. Furthermore, tyrosine hydroxylase positive cells exposed to the etoposide prodrug were effectively killed in contrast to tyrosine hydroxylase negative controls. These findings demonstrate that etoposide can be designed as a prodrug substrate for tyrosine hydroxylase and thereby establish proof of concept for neuroblastoma directed enzyme prodrug therapy.
Sujet(s)
Antinéoplasiques d'origine végétale/pharmacologie , Étoposide/pharmacologie , Neuroblastome/traitement médicamenteux , Promédicaments/métabolisme , Tyrosine 3-monooxygenase/métabolisme , Animaux , Biotransformation , Technique de Western , Survie cellulaire/effets des médicaments et des substances chimiques , Chromatographie en phase liquide à haute performance , Dopa/métabolisme , Conception de médicament , Escherichia coli/enzymologie , Humains , Souris , Neuroblastome/métabolisme , Neuroblastome/anatomopathologie , Plasmides , Promédicaments/synthèse chimique , Spécificité du substrat , Cellules cancéreuses en culture , Tyrosine/métabolisme , Tyrosine 3-monooxygenase/génétiqueRÉSUMÉ
Effective chemotherapy in neuroblastoma is limited by poor anti-tumor efficacy, systemic toxicity and the induction of drug resistance. Here, we provide further evidence that a hydrolytic activated prodrug design may overcome these problems. For this purpose, VP-16 was functionally blocked by a carbonate linker to generate two novel chemically stable prodrugs of VP-16, ProVP-16 I and II. We demonstrate profoundly different biological effects in vitro and in vivo of the prodrugs compared to parental VP-16. First, we established an up to >2 log higher in vitro toxicity of the two prodrugs compared to VP-16 on a panel of neuroblastoma cell lines. The highest increase of prodrug mediated cytotoxicity was observed in multi drug resistant cell lines. Second, in vivo studies showed a maximum tolerated dose (MTD) of ProVP-16 II (60 mg/kg), which was at least threefold higher than that of VP-16 (20 mg/kg). Tests of ProVP-16 II in a syngeneic NXS2 neuroblastoma model indicated that mice treated with this prodrug at 1/3 of the MTD was as effective as VP-16 parental compound used at the MTD in suppression of tumor growth. In summary, the etoposide prodrugs proved effective and less toxic and are therefore highly promising new anti-neuroblastoma compounds.
Sujet(s)
Antinéoplasiques d'origine végétale/pharmacologie , Étoposide/pharmacologie , Neuroblastome/traitement médicamenteux , Promédicaments/métabolisme , Animaux , Biotransformation , Survie cellulaire/effets des médicaments et des substances chimiques , Amorces ADN/composition chimique , Conception de médicament , Multirésistance aux médicaments , Résistance aux médicaments antinéoplasiques , Tests de criblage d'agents antitumoraux , Femelle , Humains , Hydrolyse , Dose maximale tolérée , Souris , Neuroblastome/métabolisme , Neuroblastome/anatomopathologie , Plasmides , Promédicaments/synthèse chimique , RT-PCR , Cellules cancéreuses en cultureRÉSUMÉ
A carcinoembryonic Ag (CEA)-based DNA vaccine encoding both CEA and CD40 ligand trimer achieved effective tumor-protective immunity against murine colon carcinoma in CEA-transgenic mice by activating both naive T cells and dendritic cells. Peripheral T cell tolerance to CEA was broken in a prophylactic model by this novel, dual-function DNA vaccine, whose efficacy was further enhanced by boosts with a recombinant Ab-IL-2 fusion protein (huKS1/4-IL-2). These conclusions are supported by four lines of evidence. First, a lethal challenge of MC38-CEA-KS Ag murine colon carcinoma cells was for the first time completely rejected in 100% of experimental animals treated by oral gavage of this DNA vaccine carried by attenuated Salmonella typhimurium, followed by five boosts with huKS1/4-IL-2. Second, specific activation of dendritic cells was indicated by their marked up-regulation in expression of costimulatory molecules B7.1 (CD80), B7.2 (CD86), and ICAM-1. Third, a decisive increase over control values was observed in both MHC class I Ag-restricted cytotoxicity of CTLs from successfully vaccinated mice and secretion of proinflammatory cytokines IFN-gamma and IL-12. Fourth, activation of CTLs was augmented, as indicated by up-regulation of activity markers LFA-1, CD25, CD28, and CD69. Taken together, these results suggest that a dual-function DNA vaccine encoding CEA and CD40 ligand trimer combined with tumor-targeted IL-2 may be a promising strategy for the rational development of DNA-based cancer vaccines for future clinical applications.
Sujet(s)
Ligand de CD40/usage thérapeutique , Vaccins anticancéreux/usage thérapeutique , Antigène carcinoembryonnaire/usage thérapeutique , Carcinomes/prévention et contrôle , Molécules d'adhérence cellulaire , Tumeurs du côlon/prévention et contrôle , Vaccins à ADN/usage thérapeutique , Animaux , Antigènes CD/biosynthèse , Antigènes néoplasiques/génétique , Antigènes néoplasiques/immunologie , Antigènes néoplasiques/usage thérapeutique , Antigène CD80/biosynthèse , Antigène CD86 , Ligand de CD40/génétique , Ligand de CD40/immunologie , Antigène carcinoembryonnaire/génétique , Antigène carcinoembryonnaire/immunologie , Molécule d'adhérence des cellules épithéliales , Interleukine-2/génétique , Interleukine-2/immunologie , Interleukine-2/usage thérapeutique , Glycoprotéines membranaires/biosynthèse , Souris , Souris transgéniques , Protéines de fusion recombinantes/immunologie , Protéines de fusion recombinantes/usage thérapeutique , Lymphocytes T cytotoxiques/immunologie , VaccinationRÉSUMÉ
We demonstrate that a mouse-human chimeric anti-ganglioside GD2-interleukin (IL)-2 fusion protein (ch14.18-IL2) substantially amplifies tumor-protective immunity against murine melanoma induced by an autologous oral DNA vaccine containing the murine ubiquitin gene fused to murine melanoma peptide epitopes gp100(25-35) and TRP-2(181-188). This combination therapy led to the complete rejection of a lethal challenge with B78D14 murine melanoma cells in six of eight mice and a marked suppression of s.c. tumor growth in the two remaining animals. The tumor-protective immunity was mediated by MHC class I antigen- restricted CD8(+) T cells together with CD4(+) T cell help, which was required only for tumor cell killing in the effector phase of the immune response. A single oral vaccination with the DNA vaccine, which was carried by attenuated Salmonella typhimurium, was equally as effective as three such vaccinations applied at 2-week intervals. The immunological mechanisms involved in this antitumor effect were suggested by a decisively increased secretion of tumor necrosis factor alpha TNFTnTNa and IFN-gamma from CD4(+) and CD8(+) T cells and a markedly up-regulated expression on CD8(+) T cells of high-affinity IL-2 receptor alpha chain (CD25), costimulatory molecule CD28, and adhesion molecule lymphocyte function-associated antigen-2 (LFA-2/CD2). Additionally, the combination therapy induced increased expression of costimulatory molecules B7.1 and CD48 on murine antigen-presenting cells. Taken together, our results suggest that IL-2 targeted to the tumor microenvironment by a specific antibody-IL-2 fusion protein is a potent enhancer of tumor-protective immunity induced by an oral DNA vaccine that may ultimately enhance the chances of success in its clinical application.
Sujet(s)
Immunotoxines/immunologie , Interleukine-2/immunologie , Mélanome expérimental/immunologie , Mélanome expérimental/prévention et contrôle , Vaccins à ADN/immunologie , Administration par voie orale , Animaux , Antigène CD80/biosynthèse , Lymphocytes T CD4+/effets des médicaments et des substances chimiques , Lymphocytes T CD4+/immunologie , Lymphocytes T CD4+/métabolisme , Lymphocytes T CD8+/effets des médicaments et des substances chimiques , Lymphocytes T CD8+/immunologie , Lymphocytes T CD8+/métabolisme , Synergie des médicaments , Épitopes/immunologie , Femelle , Gangliosides/immunologie , Humains , Immunotoxines/administration et posologie , Interféron gamma/métabolisme , Interleukine-2/administration et posologie , Intramolecular oxidoreductases/immunologie , Activation des lymphocytes/immunologie , Glycoprotéines membranaires/immunologie , Souris , Souris de lignée C57BL , Souris knockout , Protéines tumorales/immunologie , Fragments peptidiques/immunologie , Protéines de fusion recombinantes/administration et posologie , Protéines de fusion recombinantes/immunologie , Facteur de nécrose tumorale alpha/métabolisme , Vaccins à ADN/administration et posologie , Antigène gp100 du mélanomeRÉSUMÉ
Effective chemotherapy remains a key issue for successful cancer treatment in general and neuroblastoma in particular. Here we report a chemotherapeutic strategy based on catalytic antibody-mediated prodrug activation. To study this approach in an animal model of neuroblastoma, we have synthesized prodrugs of etoposide, a drug widely used to treat this cancer in humans. The prodrug incorporates a trigger portion designed to be released by sequential retro-aldol/retro-Michael reactions catalyzed by aldolase antibody 38C2. This unique prodrug was greater than 10(2)-fold less toxic than etoposide itself in in vitro assays against the NXS2 neuroblastoma cell line. Drug activity was restored after activation by antibody 38C2. Proof of principle for local antibody-catalyzed prodrug activation in vivo was established in a syngeneic model of murine neuroblastoma. Mice with established 100-mm3 s.c. tumors who received one intratumoral injection of antibody 38C2 followed by systemic i.p. injections with the etoposide prodrug showed a 75% reduction in s.c. tumor growth. In contrast, injection of either antibody or prodrug alone had no antitumor effect. Systemic injections of etoposide at the maximum tolerated dose were significantly less effective than the intratumoral antibody 38C2 and systemic etoposide prodrug combination. Significantly, mice treated with the prodrug at 30-fold the maximum tolerated dose of etoposide showed no signs of prodrug toxicity, indicating that the prodrug is not activated by endogenous enzymes. These results suggest that this strategy may provide a new and potentially nonimmunogenic approach for targeted cancer chemotherapy.
Sujet(s)
Anticorps catalytiques/métabolisme , Étoposide/pharmacocinétique , Étoposide/toxicité , Promédicaments/pharmacocinétique , Promédicaments/toxicité , Animaux , Biotransformation , Catalyse , Division cellulaire/effets des médicaments et des substances chimiques , Fructose bisphosphate aldolase/immunologie , Cinétique , Souris , Structure moléculaire , Neuroblastome , Promédicaments/synthèse chimique , Facteurs temps , Cellules cancéreuses en cultureRÉSUMÉ
The development of novel chemotherapy strategies based on prodrugs remains a major challenge for effective treatment of malignancies. We tested the hypothesis that this can be achieved by a prodrug of paclitaxel where one biologically active center, represented by the C7 hydroxyl group, was blocked by a dihydroxypropyl side chain which can be hydrolytically cleaved by a pH-dependent, slow-release mechanism. The prodrug was synthesized by condensation of solketal chloroformate with the C7 hydroxyl group of paclitaxel followed by a ring-opening reaction to the dihydroxyl derivative. The cytotoxicity of the prodrug was similar to paclitaxel, when tested in vitro against a variety of human tumor cell lines. In vitro cell cycle analysis indicated that concentrations within the micromolar range of both drug and prodrug are required to induce sufficient G2M arrest. The hydrophilic paclitaxel prodrug proved to be more than 50-fold more water soluble than the parental drug and effectively converted to paclitaxel by pH dependent hydrolysis. Importantly, the prodrug could be used at a 3-fold higher maximum tolerated dose (MTD) and revealed a markedly improved antitumor activity in mice compared to paclitaxel. Taken together, our results demonstrate, that a hydrolytically activated paclitaxel prodrug exhibits greater water solubility and superior antitumor activity than the parental drug.
Sujet(s)
Tumeurs expérimentales/traitement médicamenteux , Paclitaxel/synthèse chimique , Promédicaments/synthèse chimique , Animaux , Antinéoplasiques/synthèse chimique , Antinéoplasiques/pharmacologie , Antinéoplasiques/toxicité , Cycle cellulaire/effets des médicaments et des substances chimiques , Survie cellulaire/effets des médicaments et des substances chimiques , Stabilité de médicament , Femelle , Cellules souches hématopoïétiques/effets des médicaments et des substances chimiques , Humains , Concentration en ions d'hydrogène , Dose maximale tolérée , Souris , Souris nude , Transplantation tumorale , Tumeurs expérimentales/mortalité , Paclitaxel/pharmacologie , Paclitaxel/toxicité , Promédicaments/pharmacologie , Promédicaments/toxicité , Solubilité , Transplantation hétérologue , Cellules cancéreuses en culture/effets des médicaments et des substances chimiquesRÉSUMÉ
The successful induction of T cell-mediated protective immunity against poorly immunogenic malignancies remains a major challenge for cancer immunotherapy. Here, we demonstrate that the induction of tumor-protective immunity by IL-12 in a murine neuroblastoma model depends entirely on the CXC chemokine IFN-gamma-inducible protein 10 (IP-10). This was established by in vivo depletion of IP-10 with mAbs in mice vaccinated against NXS2 neuroblastoma by gene therapy with a linearized, single-chain (sc) version of the heterodimeric cytokine IL-12 (scIL-12). The efficacy of IP-10 depletion was indicated by the effective abrogation of scIL-12-mediated antiangiogenesis and T cell chemotaxis in mice receiving s.c. injections of scIL-12-producing NXS2 cells. These findings were extended by data demonstrating that IP-10 is directly involved in the generation of a tumor-protective CD8+ T cell-mediated immune response during the early immunization phase. Four lines of evidence support this contention: First, A/J mice vaccinated with NXS2 scIL-12 and depleted of IP-10 by two different anti-IP-10 mAbs revealed an abrogation of systemic-protective immunity against disseminated metastases. Second, CD8+ T cell-mediated MHC class I Ag-restricted tumor cell lysis was inhibited in such mice. Third, intracellular IFN-gamma expressed by proliferating CD8+ T cells was substantially inhibited in IP-10-depleted, scIL-12 NXS2-vaccinated mice. Fourth, systemic tumor protective immunity was completely abrogated in mice depleted of IP-10 in the early immunization phase, but not if IP-10 was depleted only in the effector phase. These findings suggest that IP-10 plays a crucial role during the early immunization phase in the induction of immunity against neuroblastoma by scIL-12 gene therapy.
Sujet(s)
Lymphocytes T CD8+/immunologie , Chimiokines CXC/physiologie , Thérapie génétique/méthodes , Interleukine-12/génétique , Neuroblastome/immunologie , Neuroblastome/prévention et contrôle , Inhibiteurs de l'angiogenèse/administration et posologie , Inhibiteurs de l'angiogenèse/biosynthèse , Inhibiteurs de l'angiogenèse/génétique , Animaux , Chimiokine CXCL10 , Chimiokines CXC/antagonistes et inhibiteurs , Déterminants antigéniques des lymphocytes T/immunologie , Femelle , Vecteurs génétiques/administration et posologie , Injections sous-cutanées , Interleukine-12/administration et posologie , Interleukine-12/biosynthèse , Activation des lymphocytes/immunologie , Souris , Souris de lignée A , Souris SCID , Neuroblastome/vascularisation , Neuroblastome/métabolisme , Cellules cancéreuses en culture/métabolisme , Cellules cancéreuses en culture/transplantation , Vaccins à ADN/administration et posologie , Vaccins à ADN/immunologieRÉSUMÉ
Peripheral T-cell tolerance toward human carcinoembryonic self-antigen (CEA) was broken in CEA-transgenic C57BL/6J mice by an oral CEA-based DNA vaccine. This vaccine, delivered by the live, attenuated AroA- strain of Salmonella typhimurium (SL7207), induced tumor-protective immunity mediated by MHC class I-restricted CD8+ T cells. Activation of these T cells was indicated by increased secretion of proinflammatory cytokines IFN-gamma, interleukin (IL)-12 and granulocyte/macrophage-colony stimulating factor, as well as specific tumor rejection and growth suppression in vaccinated CEA-transgenic mice after a lethal challenge with murine MC38 colon carcinoma cells. These tumor cells were double transfected with CEA and the human epithelial cell adhesion molecule (Ep-CAM)/KSA and consequently served as a docking site for a recombinant antibody-IL2 fusion protein (KS1/4-IL2) recognizing KSA. Importantly, the efficacy of the tumor-protective immune response was markedly increased by boosts with this antibody-IL2 fusion protein, resulting in more effective tumor rejection coupled with increased expression of costimulatory molecules B7.2/B7.2 and intercellular adhesion molecule 1 (ICAM-1) on dendritic cells and intensified release of proinflammatory cytokines IFN-gamma, IL-12, and granulocyte/macrophage-colony stimulating factor from T cells of successfully vaccinated CEA-transgenic C57BL/6J mice. Increased T-cell activation mediated by boosts with KS1/4-IL2 fusion protein after tumor cell challenge was further indicated by expanded expression of T-cell activation markers CD25, CD28, CD69, and LFA-1. The application of such CEA-based DNA vaccines and its further improved versions may ultimately prove useful in combination therapies directed against human carcinomas expressing CEA self-antigens.
Sujet(s)
Vaccins anticancéreux , Antigène carcinoembryonnaire/métabolisme , Vaccins à ADN , Animaux , Antigènes néoplasiques/métabolisme , Molécules d'adhérence cellulaire/métabolisme , Tumeurs du côlon/métabolisme , Cytokines/métabolisme , Molécule d'adhérence des cellules épithéliales , Facteur de stimulation des colonies de granulocytes et de macrophages/métabolisme , Humains , Immunotransfert , Molécule-1 d'adhérence intercellulaire/métabolisme , Interféron gamma/métabolisme , Interleukine-12/métabolisme , Souris , Souris de lignée C57BL , Souris transgéniques , Plasmides/métabolisme , Protéines de fusion recombinantes/métabolisme , Transfection , Cellules cancéreuses en culture , Régulation positiveRÉSUMÉ
BACKGROUND: The disruption of self-tolerance against neuroblastoma is the ultimate goal of an effective DNA-vaccine. PROCEDURE: Here we demonstrate the induction of a protective immunity against syngeneic murine NXS2 neuroblastoma in A/J mice, following vaccination with tyrosine hydroxylase (TH) derived antigens. Oral gene delivery was accomplished using an attenuated strain of Salmonella typhimurium as a carrier harboring vectors encoding for mTH antigens. RESULTS: Vaccination was effective in protecting animals from a lethal challenge with wild-type NXS2 tumor cells. CONCLUSIONS: These results provide the first evidence of the TH self antigen being recognized by T-cells and demonstrate that a TH-based DNA vaccine is a potentially useful immunotherapeutic strategy for neuroblastoma.
Sujet(s)
Neuroblastome/prévention et contrôle , Tyrosine 3-monooxygenase , Vaccins à ADN , Animaux , Techniques de transfert de gènes , Souris , Neuroblastome/immunologie , Plasmides , Tyrosine 3-monooxygenase/génétiqueRÉSUMÉ
A major goal of cancer immunotherapy is the induction of a cell-mediated antitumor response in poorly immunogenic malignancies. We tested the hypothesis that this can be achieved by cytokine gene therapy with a novel histone H2A-based transient transfection procedure. This was tested by using cytokine genes encoding for IL-2 and a single chain IL-12 (scIL-12) fusion protein in a recently developed murine neuroblastoma model. Here, we demonstrate that cytokine gene transfer of IL-2 and scIL-12 with histone H2A results in the induction of an antitumor immune response that is superior in some respects to gene transfer with Superfect, a commercially available activated dendrimer commonly used to effect transfection with plasmids. Three lines of evidence support this contention. First, histone H2A-mediated transfection of IL-2 induces a natural killer cell-induced rejection of primary tumors in contrast to Superfect, which produces only a partial reduction in primary tumor growth. Second, the induction of a T cell-mediated protective tumor immunity following gene transfer of scIL-12 is more efficient with the histone H2A-mediated gene transfer because rejection of a lethal wild-type tumor cell challenge is accompanied by the greatest degree of MHC class I-restricted tumor cell killing in vitro. Third, histone H2A-mediated scIL-12 gene therapy induces the greatest release of mIFN-gamma from splenocytes of vaccinated animals in contrast to Superfect and other controls.
Sujet(s)
Histone/génétique , Interleukine-2/génétique , Neuroblastome/thérapie , Animaux , Modèles animaux de maladie humaine , Test ELISA , Thérapie génétique , Interféron gamma/métabolisme , Souris , Neuroblastome/génétique , Neuroblastome/immunologie , Neuroblastome/anatomopathologie , Lymphocytes T cytotoxiques/immunologie , Transfection , Cellules cancéreuses en cultureRÉSUMÉ
The induction of tumor-protective immunity against malignancies remains a major challenge in cancer immunotherapy. A novel, humanized anti-ganglioside-GD(2)-IL-2 immunocytokine (hu14.18-IL-2) induced CD8(+) T cells to eradicate established pulmonary metastases of B78-D14 murine melanoma, in a process that required help by CD4(+) T cells and was mediated by the CD40/CD40 ligand (CD40L) interaction. The anti-tumor effect was diminished in mice deficient in CD4(+) T-cells. Three lines of evidence show that CD4(+) T-cell help was mediated by CD40/CD40L interaction but not by endogenous IL-2 production. First, the hu14.18-IL-2-induced anti-tumor response is partially abrogated in C57BL/6J CD40L knockout (KO) mice in contrast to C57BL/6J IL-2 KO animals, in which the immunocytokine was completely effective. Second, partial abrogation of the anti-tumor effect is induced with anti-CD40L antibodies to the same extent as with CD4(+) T-cell depletion. Third, a complete anti-tumor response induced by hu14.18-IL-2 can be reconstituted in C57BL/6J CD40L KO mice by simultaneous stimulation with an anti-CD40 mAb. These results suggest that help provided by CD4(+) T cells via CD40/CD40L interactions in our tumor model is crucial for effective immunotherapy with an IL-2 immunocytokine.
Sujet(s)
Lymphocytes T CD4+/immunologie , Antigènes CD40/physiologie , Interleukine-2/usage thérapeutique , Mélanome expérimental/thérapie , Glycoprotéines membranaires/physiologie , Animaux , Cellules présentatrices d'antigène/physiologie , Antigènes CD40/génétique , Ligand de CD40 , Femelle , Activation des lymphocytes , Mélanome expérimental/immunologie , Glycoprotéines membranaires/génétique , Souris , Souris de lignée C57BL , Souris knockoutSujet(s)
Anticorps antitumoraux/administration et posologie , Lymphocytes T CD8+/immunologie , Cytokines/administration et posologie , Adjuvants immunologiques/administration et posologie , Animaux , Vaccins anticancéreux/administration et posologie , Gangliosides/immunologie , Humains , Immunité cellulaire , Interleukine-2/administration et posologie , Tumeurs/immunologie , Tumeurs/thérapie , Protéines de fusion recombinantes/administration et posologie , Protéines de fusion recombinantes/immunologieRÉSUMÉ
Targeting of cytokines into the tumor microenvironment using antibody-cytokine fusion proteins, called immunocytokines, represents a novel approach in cancer immunotherapy. This article summarizes therapeutic efficacy and immune mechanisms involved in targeting interleukin-2 (IL-2) to neuroectodermal tumors using ganglioside GD2-specific antibody-IL-2 fusion protein (ch14.18-IL-2). Treatment of established melanoma metastases with ch14.18-IL-2 resulted in eradication of disease followed by a vaccination effect protecting mice from lethal challenges with wild-type tumor calls. In a syngeneic neuroblastoma model, targeted IL-2 was effective in the amplification of a weak memory immune response previously induced by IL-12 gene therapy using an engineered linear version of this heterodimeric cytokine. These findings show that targeted IL-2 may provide an effective tool in cancer immunotherapy and establish the missing link between T cell-mediated vaccination and objective clinical responses.